TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04231552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
Study: NCT03717428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily Weighing Group
Description: The Experimental group will weigh themselves everyday

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
Study: NCT03112954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal-relaxant formula
Description: Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
Study: NCT00655915

Intervention type: OTHER
Intervention: Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine
Description: Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
Study: NCT01147627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide injection
Description: Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R
Description: Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
Study: NCT04034797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photography teletransmission
Description: A photography of the trauma is teletransmitted to SAMU's physician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No photo
Description: Usual management without photography teletransmission
Study: NCT00973297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary falls prevention
Description: Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
Study: NCT00815854

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 5 mg of folic acid taken daily for 3 months in an open label fashion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects may receive placebo (a sugar pill) for 4 months
Study: NCT01271582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, 5FU, leucovorin
Description: FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
Study: NCT02086006

Intervention type: DEVICE
Group type: OTHER
Intervention: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
Study: NCT01160419

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel 50 mg/m2, 1-hour-Infusion, day 1
Description: 50 mg/m2, 1-hour-Infusion, day 1
Study: NCT02076022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard fat graft
Description: Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
Study: NCT01160419

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1
Description: 85 mg/m², 2-hour-Infusion, day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1
Description: 200 mg/m², 1-2-hour-Infusion, day 1
Study: NCT04756752

Intervention type: OTHER
Intervention: Fit and Vitaal program
Description: Intervention type: training
Study: NCT01160419

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU 2600 mg/m², 24-hour-Infusion, day 1
Description: 2600 mg/m², 24-hour-Infusion, day 1
Study: NCT03897140

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: Limited Echocardiogram
Description: STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
Study: NCT02379130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play and Nutrition Intervention
Description: The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
Study: NCT02921464

Intervention type: OTHER
Intervention: none - registry clinic followup only

Intervention type: OTHER
Intervention: none - registry clinic followup only
Study: NCT02082340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TB knowledge and socio-psychological counseling session
Description: TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
Study: NCT03611478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Description: Probiotic capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical in taste and appearance to probiotic capsule
Study: NCT01428830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7-day catheterization following fistula repair surgery
Description: This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 14 day catheterization
Description: This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
Study: NCT02003547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076
Study: NCT02190019

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostar repetitive transcranial magnetic stimulator
Description: The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
Study: NCT02082340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS text messages
Description: TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone calls
Description: Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
Study: NCT02003547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02082340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered drug intake strategy
Description: Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational leaflet
Description: Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
Study: NCT02114658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar,BAY43-9006)
Description: Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
Study: NCT02651753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor + Lipidil supra
Description: Reference Drug: Lipitor + Lipidil supra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor + Lipidil supra
Description: Reference Drug: Lipitor + Lipidil supra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-337
Description: Test Drug: CKD-337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-337
Description: Test Drug: CKD-337
Study: NCT05315908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community outreach method
Description: The method includes automated call and text messaging to increase testing for COVID-19

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community outreach method
Description: The method includes automated call and text messaging to increase testing for COVID-19
Study: NCT01625260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
Study: NCT02922699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMEZ 40
Description: Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMEZ 80
Description: Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
Study: NCT02449746

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed.
Study: NCT03834558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed exercise program
Description: A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed
Study: NCT01988701

Intervention type: OTHER
Intervention: Ancillary-Correlative
Description: Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
Study: NCT02190019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostar repetitive transcranial magnetic stimulator
Description: The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
Study: NCT03878433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glisodin
Description: 500 mg/day between 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
Study: NCT02870322

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fruit and Vegetable CSA Prescription
Description: Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bikeshare Prescription
Description: Study participants will use bikeshare for transportation and physical activity for 10 weeks
Study: NCT04214652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: IDP-126 Gel applied topically to the face once daily for 12 weeks.
Study: NCT03835416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Foods rich in high quality protein
Description: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Foods rich in high quality protein
Description: Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
Study: NCT01699347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracystic injection of OK432 under US guiding
Description: Intracystic injection of OK432 under US guiding
Study: NCT00313183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: single subcutaneous doses of 15mcg and 30mcg
Study: NCT00583713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BLI-800
Description: BLI-800 oral solution (two doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-800
Description: BLI-800 oral solution (two doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-800
Description: BLI-800 oral solution (two doses)
Study: NCT04214652

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-126 Vehicle Gel
Description: IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Study: NCT04159883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)
Description: Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)
Description: Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Dear Knee smart phone application
Description: The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account.
Study: NCT03189979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and healthy eating intervention
Description: Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
Study: NCT04453735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin mylan 40 Mg Oral Tablet
Description: Oral tablet on regular prescription
Study: NCT01256216

Intervention type: DEVICE
Group type: OTHER
Intervention: Total Knee Replacement with Vanguard Total Knee
Description: Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
Study: NCT04224688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants receive placebo by subcutaneous infusion at pre-specified time points.
Study: NCT01860729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Study: NCT02334150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSEA (ropivocaine and sufentanil)
Description: Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.